| [1] |
Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease [J]. Gastroenterology, 2011, 140(6):1729-1737.
|
| [2] |
Kaser A, Zeissig S, Blumberg R. Inflammatory bowel disease [J]. Annu Rev Immunol, 2010, 28(1):573-621.
|
| [3] |
Guarnieri DJ, Dileone RJ.MicmRNAs：a new class of gene regulators [J]. Ann Med, 2008, 40(3):197-208.
|
| [4] |
Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease [J]. Inflamm Bowel Dis, 2012, 18(1):187-193.
|
| [5] |
Polytarchou C, Oikonomopoulos A, Mahurkar S, et al. Assessment of Circulating MicroRNAs for the Diagnosis and Disease Activity Evaluation in Patients with Ulcerative Colitis by Using the Nanostring Technology [J]. Inflamm Bowel Dis, 2015, 21(11):2533-2539.
|
| [6] |
Felwick R., Dingley G., Sanchez-Elsner T., et al. MicroRNA23a is overexpressed in the colonic epithelium in Crohn′s disease [J]. Journal of Crohn′s and Colitis , 2016, 150(4):S375-S375.
|
| [7] |
Yu Q, Zhang S, Chao K, et al. E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease [J]. J Crohns Colitis, 2016, 10(6):713-725.
|
| [8] |
Wu W, He C, Liu C, et al. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD [J]. Gut, 2015, 64(11):1755-1764.
|
| [9] |
Takagi T, Naito Y, Mizushima K, et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis [J]. J Gastroenterol Hepatol, 2010, 25(1):S129-S133.
|
| [10] |
Heinsbroek SE, Squadrito ML, Schilderink R, et al. miR-511-3p, embedded in the macrophage mannose receptor gene, contributes to intestinal inflammation [J]. Mucosal Immunol, 2016, 9(4):960-973.
|
| [11] |
Zhang L, Shen J, Cheng J, et al. MicroRNA-21 regulates intestinal epithelial tight junction permeability [J]. Cell Biochem Funct, 2015, 33(4):235-240.
|
| [12] |
Yang Y, Ma Y, Shi C, et al. Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase RhoB [J]. Biochem Biophys Res Commun, 2013, 434(4):746-752.
|
| [13] |
Ye D, Guo S, Al-Sadi R, et al. MicroRNA regulation of intestinal epithelial tight junction permeability [J]. Gastroenterology, 2011, 141(4):1323-1333.
|
| [14] |
Chen Y, Wang C, Liu Y, et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn′s disease [J]. Biochem Biophys Res Commun, 2013, 438(1):133-139.
|
| [15] |
Schaefer JS, Attumi T, Opekun AR, et al. MicroRNA signatures differentiate Crohn′s disease from ulcerative colitis [J]. BMC Immunol, 2015, 16(1):5.
|
| [16] |
Krissansen GW, Yang Y, Mcqueen FM, et al. Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease [J]. Inflamm Bowel Dis, 2015, 21(3):520-530.
|
| [17] |
Yu N, Zhang YP, Wang FY. Differential expression of miR-155 as a novel fecal-based diagnostic marker for inflammatory bowel disease [J]. J Dig Dis, 2014, 15, SUPPL. (1):156.
|
| [18] |
Yi F, Zhou R, Xun J, et al. The utility of fecal microRNAs and S100A12 in the diagnosis of inflammatory bowel disease [J]. J Gastroenterol Hepatol, 2013, 28 SUPPL. (3):146.
|
| [19] |
Iborra M, Bernuzzi F, Correale C, et al. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease [J]. Clin Exp Immunol, 2013, 173(2):250-258.
|
| [20] |
Wang H, Zhang S, Yu Q, et al. Circulating MicroRNA223 is a New Biomarker for Inflammatory Bowel Disease [J]. Medicine(Baltimore), 2016, 95(5):e2703.
|
| [21] |
Link A, Schoenauen K, Le N, et al. Differential expression of micrornas in sera and feces of patients with inflammatory bowel disease [J]. United Eur Gastroenterol J, 2015, 3(5):A236-A237.
|
| [22] |
Pott F, Cichon C, Brückner M, et al. MicroRNA-320 as a biomarker to monitor the course of disease activity in experimental colitis as well as in patients with inflammatory bowel disease [J]. United Eur Gastroenterol J, 2(1):A214.
|
| [23] |
Ibrahim AF, Weirauch U, Thomas M, et al. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma [J]. Cancer Res, 2011, 71(15):5214-5224.
|
| [24] |
Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection [J]. Science, 2010, 327(5962):198-201.
|
| [25] |
Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha [J]. Gastroenterology, 2008, 135(5):1624-1635.
|
| [26] |
Simonson B, Das S. MicroRNA Therapeutics: the Next Magic Bullet? [J]. Mini Rev Med Chem, 2015, 15(6):467-474.
|
| [27] |
Viscido A, Bagnardi V, Sturniolo GC, et al. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study [J]. Dig Liver Dis, 2001, 33(8):686-692.
|
| [28] |
Feagins L A, Souza R F, Spechler S J. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer [J]. Nat Rev Gastroenterol Hepatol, 2009, 6(5):297-305.
|
| [29] |
Ludwig K, Fassan M, Mescoli C, et al. PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis [J]. Virchows Arch, 2013, 462(1):57-63.
|
| [30] |
Ranjha R, Aggarwal S, Bopanna S, et al. Site-Specific MicroRNA Expression May Lead to Different Subtypes in Ulcerative Colitis [J]. PLoS One, 2015, 10(11):e142869.
|
| [31] |
Olaru AV, Selaru FM, Mori Y, et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation [J]. Inflamm Bowel Dis, 2011, 17(1):221-231.
|
| [32] |
Olaru AV, Yamanaka S, Vazquez C, et al. MicroRNA-224 negatively regulates p21 expression during late neoplastic progression in inflammatory bowel disease [J]. Inflamm Bowel Dis, 2013, 19(3):471-480.
|
| [33] |
Kunte D, Savkovic S, Qi W, et al. MiR-34a as potential fecal biomarker Colitis-induced Colorectal cancer [J]. Inflammatory Bowel Dis, 2011, 17: S86-S87.
|